frequency therapeutics hearing loss drug development

Frequency Therapeutics Announces Successful Completion of First-in-Human Study of FX-322, Company’s Leading Candidate for Hearing Restoration

WOBURN, MASSACHUSSETTS – Biotech startup, Frequency Therapeutics, announced late last month the successful completion of a first-in-human study of the company’s investigative compound FX-322, the company’s lead Progenitor Cell Activation (PCA) candidate for hearing restoration. The preliminary results were recently presented at a lecture last month at the US-Japan Symposium on Drug Delivery. According to…

Read More

Startup Gets $52 Million Investment to Develop Drug Treatment for Hearing Loss

BOSTON, MASSACHUSETTS – Third Rock Ventures, a biotechnology-focused venture capital firm located in Boston, announced the launch of a new startup company with the sole purpose of treating hearing loss. The new company, Decibel Therapeutics, raised $52 million dollars in Series A funding for its launch, with investment from Third Rock Ventures and SR One—the venture capital arm of…

Read More

As hearing industry seeks a new wireless standard for hearing aids, t-coil advocates say not so fast

Since this post was originally published on April 30, it has drawn a number of thoughtful and provocative comments, which follow the main text.  This revised post also contains a response from Jan Topholm, a prominent EHIMA member,  to a query that I sent him in writing the original post.   By David H. Kirkwood…

Read More

New web site on tinnitus

NEW YORK–The Hearing Health Foundation has launched a web site focusing on tinnitus. There, people who have the condition as well as healthcare professionals can learn more about tinnitus, which chronically affects 5% to 10% of the U.S. adult population. The site discusses the causes of tinnitus and explains the various treatments available to people…

Read More